. . . AND ZERO

Pascal Soriot Chief executive, AstraZeneca THE AstraZeneca boss saw shares in his firm crash 15pc this week after clinical trials of a new lung cancer drug flopped.

The Frenchman, 58, refuses to set a date for when he plans to stand down. Will shareholders decide on one for him?